多参数乳腺MRI用于解决钼靶检测到的可疑钙化问题
该前瞻性研究纳入81例女性86处钼靶可疑钙化,评估多参数乳腺MRI(DCE-MRI和DWI)在活检前区分恶性病变的表现。MRI定性特征结合临床和钼靶特征的多变量模型AUC高于仅用临床和钼靶特征(恶性:0.71-0.76 vs 0.57;浸润癌或高级别DCIS:0.78-0.91 vs 0.61,均p<0.05)。进一步加入DWI或定量MRI特征未提高AUC(所有ΔAUC≤0)。
要点
- 钼靶BI-RADS 4a和4b无强化钙化的恶性率分别为3.8%(1/26)和8.7%(2/23),均无浸润癌或高级别DCIS。
- MRI BI-RADS类别、DWI可见性、峰值强化百分比、功能肿瘤体积和Ktrans值与恶性及浸润癌/高级别DCIS均相关(均p<0.05)。
- 包含DCE-MRI定性评估的多变量模型AUC高于仅临床和钼靶特征模型,加入DWI或定量特征未进一步改善。
核心结论
- 乳腺DCE-MRI有助于评估钼靶BI-RADS 4a/4b钙化而避免活检;DWI或定量MRI特征可能不会进一步提高诊断性能。
研究设计与样本
- 前瞻性研究,2017年8月至2023年5月纳入81例女性86处钼靶可疑钙化,活检前行多参数MRI(标准和高时间分辨率DCE-MRI及DWI)。
诊断标准与关键数值
- 钼靶BI-RADS 4a无强化钙化恶性率为3.8%(1/26),4b无强化钙化恶性率为8.7%(2/23),均无浸润癌或高级别DCIS。
- 包含DCE-MRI定性评估的多变量模型AUC:恶性为0.71-0.76,浸润癌或高级别DCIS为0.78-0.91。
- 仅包含临床和钼靶特征的多变量模型AUC:恶性为0.57,浸润癌或高级别DCIS为0.61,与包含MRI定性特征的模型差异均p<0.05。
- 进一步加入DWI或定量MRI特征未提高AUC(所有ΔAUC≤0)。
临床应用与阅片要点
- 对于钼靶BI-RADS 4a/4b可疑钙化,乳腺DCE-MRI可辅助评估以避免活检。
- DWI或定量MRI特征可能不会进一步提高诊断性能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the performance of multiparametric breast MRI to problem-solve mammographically-detected suspicious calcifications.
MATERIALS AND METHODS: Participants with mammographically-detected suspicious calcifications were prospectively enrolled between August 2017 to May 2023. Pre-biopsy multiparametric MRI (standard and high-temporal resolution dynamic contrast enhanced [DCE]-MRI acquisitions and diffusion-weighted imaging [DWI]) was performed. The associations of MRI features with outcomes - (1) any malignancy and (2) invasive or high-grade ductal carcinoma in situ [DCIS] only - were analyzed using univariable logistic regression. Multivariable models, sequentially incorporating clinical/mammographic, qualitative, and quantitative features, were developed using penalized logistic regression with the least absolute shrinkage and selection operator. Area under the receiver operating characteristic curves (AUC) were estimated via cross-validation and compared between models using bootstrap methods.
RESULTS: 81 women (mean age, 55 years ± 10 [standard deviation]) with 86 calcifications were included; 29 % (25/86) were malignant. Malignancy rates for non-enhancing mammographic Breast Imaging Reporting and Data System (BI-RADS) category 4a and 4b calcifications were 3.8 % (1/26) and 8.7 % (2/23), respectively, with no invasive cancer or high-grade DCIS. Mammographic BI-RADS category, MRI BI-RADS category, visibility on DWI, peak percent enhancement, functional tumor volume, and Ktrans values were associated with both outcomes (all p < 0.05). Multivariable models, including qualitative DCE-MRI assessments, showed higher AUCs (malignancy: 0.71-0.76; invasive cancer or high-grade DCIS: 0.78-0.91) than when including only clinical and mammographic features (malignancy: 0.57; invasive cancer or high-grade DCIS: 0.61, all p < 0.05). Further incorporation of DWI or quantitative MRI features did not improve AUCs (all ΔAUC ≤ 0).
CONCLUSION: Breast DCE-MRI aids in evaluating mammographic BI-RADS category 4a/4b calcifications without biopsy. DWI or quantitative MRI features may not further improve diagnostic performance.
引用
- Park VY, Hippe DS, Kazerouni AS, et al. Multiparametric breast MRI to problem-solve mammographically detected suspicious calcifications. Eur J Radiol. 2025. PMID: 41108951. doi:10.1016/j.ejrad.2025.112467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。